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Correspondence: Gabriella Misso, Department of Precision Medicine, UniversitymiR-125b, ubiquitously expressed and frequently dysregulated
in several tumors, has gained special interest in the ﬁeld of can-
cer research, displaying either oncogenic or oncosuppressor
potential based on tumor type. We have previously demon-
strated its tumor-suppressive role in multiple myeloma
(MM), but the analysis of molecular mechanisms needs addi-
tional investigation. The purpose of this study was to explore
the effects of miR-125b and its chemically modiﬁed analogs
in modulating cell viability and cancer-associated molecular
pathways, also focusing on the functional aspects of stress
adaptation (autophagy and senescence), as well as programmed
cell death (apoptosis). Based on the well-known lowmicroRNA
(miRNA) stability in therapeutic application, we designed
chemically modiﬁed miR-125b mimics, laying the bases for
their subsequent investigation in in vivo models. Our study
clearly conﬁrmed an oncosuppressive function depending on
the repression of multiple targets, and it allowed the identiﬁca-
tion, for the ﬁrst time, of miR-125b-dependent miR-34a stim-
ulation as a possible consequence of the inhibitory role on the
interleukin-6 receptor (IL-6R)/signal transducer and activator
of transcription 3 (STAT3)/miR-34a feedback loop. Moreover,
we identiﬁed a pattern of miR-125b-co-regulated miRNAs,
shedding light on possible new players of anti-MM activity.
Finally, functional studies also revealed a sequential activation
of senescence, autophagy, and apoptosis, thus indicating, for
the ﬁrst two processes, an early cytoprotective and inhibitory
role from apoptosis activation.of Campania “Luigi Vanvitelli,” 80138 Naples, Italy.
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Over the last decade, the biology of multiple myeloma (MM) has been
extensively studied to deﬁne the complex interplay between theMolecular T
This is an open access article under tsignaling pathways accountable for its intricate physiopathology.
MM is supported by the bone marrow microenvironment (BMM),
since it can promote myeloma growth and survival, and it is also
responsible for bone damage, the most common clinical feature in
MM patients.1 It is noteworthy that more than 80%–90% of MM pa-
tients develop bone involvement;2 other hallmarks include hypercal-
cemia, renal dysfunction, and anemia.2 The earliest phase before the
development of symptomatic MM is termed monoclonal gammop-
athy of undetermined signiﬁcance (MGUS).3 Another asymptomatic
phase following MGUS is smoldering MM (SMM), characterized by a
10% average risk of progression to myeloma per year for the ﬁrst
5 years from the occurrence of the disease, decreasing to 3% per
year for the next 5 years and to 1%–2% per year for the next 10 years.4
When pre-malignant disorders evolve into MM, the overt symptoms
arise with clinically relevant end-organ damage related to the plasma
cell proliferative disorder.5
The ﬁnal phase is plasma cell leukemia (PCL), an aggressive disease
endpoint characterized by the existence of extramedullary clonesherapy: Nucleic Acids Vol. 16 June 2019 ª 2019 The Authors. 391
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Molecular Therapy: Nucleic Acidsand rapid progression to death.5 In detail, bone disease occurs when
plasma cells directly interact with the BMM, which results in an
increased rate of osteoclast-mediated bone resorption and decreased
osteoblast-mediated bone formation.2 This imbalance is caused by the
dysregulation of several cytokines, chemokines, growth factors, and
other components secreted by bone marrow stromal cells (BMSCs),
which contribute to a symbiotic cycle that maintains anMM-promot-
ing microenvironment and allows the tumor cells to secrete inter-
leukin-1b (IL-1b), tumor necrosis factor alpha (TNF-a), transform-
ing growth factor b (TGF-b), VEGF, and interleukin-6 (IL-6).6
Binding of IL-6 to the IL-6 receptor (IL-6R) triggers the activation
of at least three signaling pathways: the Janus kinase (JAK)/signal
transducer and activator of transcription (STAT) pathway, the Ras/
mitogen-activated protein kinase (MAPK) pathway, and the PI3K/
Akt pathway.7,8
The identiﬁcation of the key role exerted by the BMM in support of
MM cell growth and survival has opened the way to innovative
target-based therapeutic approaches. In this context, microRNAs
(miRNAs) are promising tools not only for the early detection but
also for the treatment of MM. miRNAs act either as oncogenes
(oncomiR) or tumor suppressors, regulating simultaneously the
expression of multiple target genes.9–11 The main challenge for an
effective miRNA-based therapy still includes the effective delivery
of the appropriate miRNA to the BMM and its uptake by malignant
plasma cells in the absence of off-target effects.12 Potential strategies
based on miRNA therapeutics basically rely on miRNA inhibition or
miRNA replacement approaches and take beneﬁt respectively from
the use of synthetic miRNAs13–17 or speciﬁc miRNA inhibitors.18–20
Among the miRNAs dysregulated in MM, not much is known about
miR-125b function, except the reported inactivation of p53,21,22
suggestive of an oncogenic role. However, divergent experimental
evidence has demonstrated the tumor-suppressive function of miR-
125b in the U266 MM cell line, since its transduction was able to
induce a signiﬁcant increase in death rate compared to control cells
by the downregulation of BLIMP-1, IRF4, and SYNDECAN-1
(CD138), a cell surface molecule expressed by myeloma and primary
plasma cells.23 We have previously demonstrated that miR-125b was
deregulated in TC2/3 molecular subtypes of MM. Moreover, anti-
myeloma activity was achieved via direct downregulation of IRF4
and its downstream effector BLIMP-1. All together these ﬁndings
led us to conclude that miR-125b has tumor suppressor activity
and offers a new means for miRNA replacement strategies.24
The need to generate additional information into the biology of miR-
125b in the translational perspective has prompted us to carry out the
present study. The basic premise of our work was the identiﬁcation,
in TargetScan (http://www.targetscan.org/vert_72/), of a series of
appealing predicted miR-125b targets; among them we recognized
the main promoter and effector factors responsible for maintaining
the myeloma microenvironment and for conferring resistance to con-
ventional therapies. Moreover, functional studies have also proven
useful in identifying a temporal correlation in the activation of auto-
phagy, senescence, and apoptosis. This cross-regulation has its roots392 Molecular Therapy: Nucleic Acids Vol. 16 June 2019in a series of studies showing that, in senescent cells, autophagy serves
as a mechanism of adaptation to stress; in fact, autophagosomes have
been shown to accumulate in senescent ﬁbroblasts to facilitate the
renewal of cytosolic compounds and organelles.25,26 Otherwise,
apoptosis resistance of both autophagic and senescent cells is well
documented in the literature.27–29
In detail, here we have analyzed the antiproliferative in vitro activity
promoted by miR-125b and its synthetic analogs, correlating it with
the p53 mutational status and with the expression of several targets
with regulatory function on multiple intracellular pathways activated
by growth stimuli. We have exploited a series of chemical modiﬁca-
tions (20-O-Methylation [20-Omet], 20-Fluorination [20-F] or locked
nucleic acid [LNA]) aimed at both improving the resistance to nucle-
ases and increasing the stability and binding speciﬁcity of the mRNA-
miRNA duplex.30,31 Our experimental results have allowed us to
identify the best chemical modiﬁcations in terms of anti-myeloma ac-
tivity, laying the bases for a subsequent use of such compounds in
in vivo models to assess the actual biological stability. Moreover, we
have shed light on the co-regulation of multiple miRNAs, performing
miRNome-wide expression proﬁling. Thereafter, we validated the ef-
fects of miR-125b, as well as of its modiﬁed analogs, in modulating the
expression of the tumor suppressor miR-34a, identifying, for the ﬁrst
time, a regulatory loop between these two miRNAs. Finally, based on
the current knowledge that describes senescence as a process that can
trigger autophagy as a mechanism of adaptation to stress25–32 and, at
the same time, as a process that reduces cell reactivity to apoptotic
stimuli,33 functional studies were performed to analyze the effect of
miR-125b ectopic expression on the modulation of both stress adap-
tation (autophagy and senescence) and programmed cell death
(apoptosis) in MM cells, identifying a sequential activation of these
processes.
RESULTS
Mutational Analysis of MM Cells
The identiﬁcation of common and rare genomic variants in candidate
regions of the human genome is essential to better understand the
complex human disease etiology. Mutational analysis of U266,
SKMM-1, and RPMI 8226 MM cell lines was performed as described
in the Materials and Methods. Genetic proﬁling of the MM cell
lines has highlighted deleterious mutations in several genes involved
in cell proliferation and differentiation processes. Next-generation
sequencing (NGS) was performed on the Ion Torrent PGM, using a
panel that contains amplicons to detect currently known cancer-
associated mutations in tumor driver genes. Data obtained showed
that U266 cells are mutated in MET, TP53, and BRAF genes;
SKMM-1 cells are mutated in CSDE1 (NRAS upstream gene),
PTEN, and TP53; RPMI 8226 cells are mutated in a greater number
of mutated genes, in particular ERBB4, PIK3CA, EGFR, KRAS,
and TP53. The results of molecular investigations are summarized
in Table S1.
All three lines showed single-nucleotide variants (SNVs) in the TP53
gene, but they are different from one another. Furthermore, three new
www.moleculartherapy.orgmutations, designated as novel, have been found. Somatic mutations
in the TP53 gene are one of the most frequent alterations in human
cancers, and the diverse types and positions may inform on the nature
of mutagenic mechanisms involved in cancer etiology. To clarify the
clinical and functional impacts of these variants, a literature search
was done using the principal TP53 variants database IARC TP53
Database (R18 version)34 (Table S2). Two mutants (p.R175G in
SKMM-1 and p.E285K in RPMI 8226) showed a complete loss of
transactivation activities, onemutant (p.A161T in U266) was partially
functional, and two mutants (p.A161fs in U266 and p.P72R in
SKMM-1) showed an unknown effect.
miR-125b Expression in MM Cell Lines
To select an MM cell system suitable for the study of biological effects
induced by miR-125b replacement, we analyzed, by qRT-PCR, basal
miR-125b expression in a panel of ﬁve MM cell lines (RPMI 8266,
KMS-12, OPM-2, SKMM-1, and U266). We observed that RPMI
8266 and KMS-12 cells had signiﬁcantly higher miR-125b levels
compared to OPM-2, SKMM-1, and U266 cell lines. In detail, miR-
125b expression was, respectively, 20- and 45-fold higher in KMS-
12 and RPMI 8226 cell lines, if compared to U266 cells (Figure 1A).
Moreover, no signiﬁcant differences in miR-125b levels were
observed among U266, OPM-2, and SKMM-1 cell lines.
Design of Chemically Modified Oligonucleotides
Improvement of miRNA stability is a key prerequisite to perform an
effective replacement strategy. Therefore, we exploited a series of
chemical modiﬁcations at the 20 position of ribose (Figure 1B) to in-
crease both the nucleases’ resistance in the biological environment
and the stability and/or binding speciﬁcity of the miRNA-mRNA
duplex.30 It is well known that most of RNA degradation mechanisms
catalyzed by nucleases involve the 20-OH of the ribose moiety;
therefore, chemical modiﬁcations at this site produce a considerable
stabilization. Moreover, it is noteworthy that the introduction of a
chemical moiety in the 20 position favors the typical double-helix
conformation of the miRNA-mRNA duplex.30,31 Given these as-
sumptions, we introduced the following chemical modiﬁcations in
the sugar moiety of miR-125b: 20-Omet, 20-F, and LNA. LNA com-
prises a class of bicyclic RNA analogs in which the furanose ring in
the sugar-phosphate backbone is chemically locked in an RNA
mimicking N-type (C30 endo) conformation by the introduction of
a 20-O, 40-C methylene bridge, which favors RNA A-type duplex
geometry. This modiﬁcation signiﬁcantly increases Tm (melting tem-
perature) and is also very resistant to nuclease. Due to the large in-
crease in Tm conferred by LNAs, they also increase primer dimer
as well as self-hairpin formation. These modiﬁed oligonucleotides,
along with unmodiﬁed miR-125b mimic, were subsequently tested
for miRNA replacement in our MM cellular models.
miR-125b Ectopic Expression in MM Cells Affects Cell Viability
Based on qRT-PCR data and on the different transfection efﬁciencies
showed by the MM cell lines (Figures S1A and S1B), we selected
SKMM-1 and U266 cells exhibiting low miR-125b levels and RPMI
8226 cells expressing the highest miRNA levels. These cell lineswere transiently transfected by electroporation either with miRNA
scramble (miR-NC), used as a negative control, or with synthetic
miR-125b mimic or its modiﬁed analogs. miRNAs were transfected
at a ﬁnal concentration of 100 nM that was selected on the basis of
previous standardization procedures. The subsequent effects on cell
viability and proliferation were evaluated at 24 and 48 h from trans-
fection by trypan blue exclusion dye (Figures 1C and 1H) and byMTS
assay (Figures S2A–S2C).
We observed that miR-125b replacement in the U266 cell line (Fig-
ures 1C and 1D; Figure S2A) induced, already after 24 h, a signiﬁcant
decrease in cell viability. In detail, transfection with miR-125b or
miR-125b-LNA caused a 40% reduction in cell viability compared
to control (CTR, untreated cells); a further decrease was observed
with miR-125b-20F transfection, but the highest viability inhibition
(more than 70%) was induced by miR-125b-Omet. This inhibitory ef-
fect was even more pronounced 48 h after electroporation.
Analysis of viability in the SKMM-1 cell line (Figures 1E and 1F; Fig-
ure S2B), performed under the same experimental conditions, also
showed signiﬁcant perturbation, consisting of a 60% reduction
compared to CTR, at both 24 and 48 h after electroporation with
miR-125b. Similar results were obtained when cells were transfected
with miR-125b-Omet, whereas miR-125b-20F induced a slightly
lower inhibition after 24 h and a powerful inhibitory effect at 48 h.
miR-125b-LNA induced a less pronounced cell growth inhibition.
Finally, for RPMI 8226, a weak decrease in cell viability was observed
after replacement with miR-125b, although a more pronunced anti-
proliferative effect was achieved by chemically modiﬁed miRNAs.
In detail, miR-125b-20F induced the most signiﬁcant cell viability
reduction (about 50%) at 24 h after electroporation (Figures 1G
and 1H; Figure S2C). At 48 h, the percentage of viability inhibition
was between 20% and 25% for miR-125b, miR-125b-LNA, and
miR-125b-20F transfections and up to 50% for miR-125b-Omet,
respectively.
These data demonstrate that, for the analyzed MM cell lines, we can
establish a correlation between basal miR-125b levels and the effect
on viability induced by miRNA replacement. In fact, RPMI 8226 cells,
which express high basal miR-125b levels, were not affected by
enforced miRNA expression. Moreover, among the modiﬁed analogs,
miR-125b-Omet appeared to be the most effective in inducing anti-
proliferative effects.
miRNA Profiling in miR-125b-Transfected Cells
On the basis of qRT-PCR data, as well as on cell responsiveness to
replacement, we selected the U266 cell line to study, by qRT-PCR
array cards, the modulation of a set of highly characterized miRNAs
(Figure 2A). Of the 384 tested miRNAs, excluding the 3 endogenous
controls and the 6 negative controls, 161 were expressed in the
analyzed populations. Stringent criteria were used to identify differ-
entially expressedmiRNAs with a Ct value above 10 and below 32. Ac-
cording to this, more than 2-fold altered expression compared toMolecular Therapy: Nucleic Acids Vol. 16 June 2019 393
Figure 1. miR-125b Levels in MM Cell Lines and Cell Viability Modulation after miR-125b Mimic and Its Modified Analog Transfection
(A) Analysis of basal miR-125b levels by qRT-PCR in SKMM-1, RPMI 8226, U266, OPM-2, and KMS-12 cell lines. Each experiment was repeated at least three times
and data are shown asmean ±SD. (B) Schematic representation of chemical modifications: 20-O-Methylation, 20-Fluorination, and locked nucleic acid (LNA) were introduced
in the sugar moiety of miR-125b mimics. (C–H) Trypan blue cell assay of MM cell lines transfected with 100 nMmiR-125b, miR-NC, miR-125b-Omet (Omet), miR-125b-LNA
(LNA), or miR-125b-20F (F). MM cell lines U266 (C and D), SKMM-1 (E and F), and RPMI 8226 (G and H) were analyzed after 24 h (C, E, and G) and 48 h (D, F, and H)
from transfection. CTR, untreated cells used as control. Each experiment was repeated at least three times and the data are shown as a mean ± SD. *p% 0.05, **p% 0.01,
***p% 0.001.
Molecular Therapy: Nucleic Acidscontrol (miR-NC-transfected cells) was observed for 36 miRNAs
(excluding the same miR-125b). Among these, 28 were upregulated
and 8 downregulated. In detail, within the upregulated miRNAs, 23
were expressed between 2- and 3-fold more than control, 4 between
3- and 5-fold, and 1 over 5-fold. Within the downregulated miRNAs,
3 were expressed between 2- and 3-fold less than control and 5 be-
tween 3- and 5-fold less (Table 1).394 Molecular Therapy: Nucleic Acids Vol. 16 June 2019We focused our attention on the 11 up- or downregulated more than
3-fold (Figure 2B). All these miRNAs have been already characterized
for their role in cancer, but not all of them have already been deﬁned
for a speciﬁc function in MM. Let-7c, encoded at the same cluster
(21q21) of miR-125b, plays an oncosuppressive role in several can-
cers; its expression is reduced in both tissue and sera of breast cancer
patients, hypothesizing for this miRNA a role as novel and valuable
Figure 2. miRNA Profile in U266 Cells Overexpressing
miR-125b versus NC-Transfected Cells
(A) Analysis of differentially expressed miRNAs between
U266 cells transfected with 100 nM miR-125b or miR-NC
for 48 h. Histogram shows all up- and downregulated
miRNAs whose Ct values are between 10 and 32 and their
corresponding fold change. (B) Expression levels of the
significant up- and downregulated miRNAs after 100 nM
miR-125b or miR-NC transfection for 48 h in U266 cells.
Fold changes were relative to miR-125b-transfected cells
matched with control (NC-transfected) cells. Only miRNA
expression fold changes >3 are presented in this graph.
www.moleculartherapy.orgdiagnostic biomarker.35 Let-7c expression is also downregulated in
castration-resistant prostate cancer cells, where its ectopic expression
induced growth arrest and, in parallel, its suppression enhanced
the ability of androgen-sensitive prostate cancer cells to grow in
androgen-deprived conditions.36 An oncosuppressive role was
recently observed also in cholangiocarcinoma.37 The member of the
miR-125b seed family, miR-125a-5p, that induces oncosuppression
and chemosensitization, respectively, in non-small-cell lung andMolecularbreast cancers,38,39 was also upregulated after
miR-125b replacement. A cancer-related tu-
mor-suppressive (glioma and ovarian can-
cer40,41) or tumor-promoting (gastric and hepa-
tocellular cancers42,43) effect was also registered
in previous studies for another signiﬁcantly upre-
gulated miRNA, miR-424. Among the downre-
gulated miRNAs, a group of evidence demon-
strated that miR-218 plays pivotal roles in
tumorigenesis by targeting many oncogenes
related to proliferation, apoptosis, and inva-
sion.44 Also miR-224 has a well-known role in
promoting migration and invasion,45 and it con-
tributes to the malignant progression of lung
cancer, meningioma, and hepatocellular carci-
noma.46–48 miR-495 induces cell proliferation,
invasion, and migration in both gastric49 and
bladder cancers,50 but an opposite effect was
observed in colorectal cancer.51 Both miR-539
and miR-542-3p have been shown to have an on-
cosuppressive function in several cancers,52–55
although their role is still poorly explored and,
speciﬁcally, their function in MM has not been
investigated. Even less deﬁned is the role of
miR-518f, which was found to be, together with
28 other miRNAs, signiﬁcantly downregulated
in an in vitro-selected highly invasive endome-
trial cancer cell line.56 Among the most upregu-
lated miRNAs, we found the well-known onco-
suppressor miR-34a, which contributes to p53
downstream effects on proliferation arrest
and apoptosis induction, by targeting c-MYC,
CDK6, and c-MET.9 We have previously demon-strated its downregulation in MM, where, in addition, its ectopic
expression was able to down-modulate both Erk and Akt pathways
and also to induce apoptosis through pro-caspase-6 and -3 cleavage.14
Our results from miRNome analysis offer for the ﬁrst time an inter-
esting overview of miRNA co-regulation in MM after miR-125b
replacement, and they reveal the involvement of a number of miRNAs
whose roles had been hitherto unexplored in this neoplasm.Therapy: Nucleic Acids Vol. 16 June 2019 395
Table 1. Upregulated and Downregulated miRNAs in miR-125b-
Transfected Cells Compared to miR-NC-Transfected Cells
miRNA Fold Change Modulation
hsa-let-7a 2.95 upregulated
hsa-let-7c 3.72 upregulated
hsa-let-7d 2.38 upregulated
hsa-let-7e 2.65 upregulated
hsa-miR-18a 2.12 upregulated
hsa-miR-28 2.18 upregulated
hsa-miR-29b 2.51 upregulated
hsa-miR-29c 2.51 upregulated
hsa-miR-34a 4.20 upregulated
hsa-miR-96 2.51 upregulated
hsa-miR-100 2.035 upregulated
hsa-miR-101 2.17 upregulated
hsa-miR-105 2.09 upregulated
hsa-miR-125a-5p 3.07 upregulated
hsa-miR-132 2.36 upregulated
hsa-miR-139-5p 2.07 upregulated
hsa-miR-142-3p 2.24 upregulated
hsa-miR-199a-3p 2.72 upregulated
hsa-miR-218 4.86 downregulated
hsa-miR-224 3.84 downregulated
hsa-miR-296 2.38 upregulated
hsa-miR-335 2.13 upregulated
hsa-miR-339-5p 2.42 upregulated
hsa-miR-362-3p 2.02 upregulated
hsa-miR-381 2.97 downregulated
hsa-miR-424 5.66 upregulated
hsa-miR-449b 2.29 upregulated
hsa-miR-495 4.48 downregulated
hsa-miR-512-3p 2.24 downregulated
hsa-miR-518f 3.45 downregulated
hsa-miR-532-3p 2.02 upregulated
hsa-miR-539 4.92 downregulated
hsa-miR-542-3p 3.06 downregulated
hsa-miR-671-3p 3.10 upregulated
hsa-miR-886-3p 2.97 upregulated
hsa-miR-886-5p 2.36 upregulated
Molecular Therapy: Nucleic AcidsmiR-34a Expression in MM Cell Lines
Taking into account the ubiquitous oncosuppressive role of miR-34a
and, more speciﬁcally, also the widely investigated molecular mecha-
nisms mediating its anti-MM activity, already reported in our previ-
ous papers,13,14,16,17 we have validated the actual stimulatory effect of
miR-125b on miR-34a expression. First, we analyzed basal miR-34a
levels in all MM cell lines by qRT-PCR. We found that, as for miR-
125b, also miR-34a was largely expressed in the RPMI 8226 cell396 Molecular Therapy: Nucleic Acids Vol. 16 June 2019line, while U266 and OPM-2 expressed lower and similar basal levels
of miR-34a, whose expression exceeded, in turn, 2.8-fold and 8.2-fold,
respectively, the expression levels in KMS-12-PE and SKMM-1 cells
(placing U266 miR-34a levels as unitary value) (Figure 3A). There-
after, we performed a qRT-PCR on the U266 cell line at 24 h from
transfection with or without miR-NC or miR-125b (Figure 3B). Sup-
porting our preliminary microarray data, miR-125b replacement
induced an almost 4-fold upregulation of miR-34a.
Hence, a putative miR-125b-mediated tumor-suppressive role in our
cell model could be due, at least in part, to the increase in miR-34a
expression.
Modulation of miR-125b Targets in the U266 Cell Line
U266 cells transfected withmiR-NC ormiR-125b wild-type were pro-
cessed for the analysis of the main tumor promoter and tumor-sup-
pressive miR-125b targets identiﬁed by the TargetScan platform
and recent literature (Table 2). In detail, cells electroporated either
with miR-125b or its modiﬁed analogs (see Figure S3 for transfection
efﬁciency) were processed for western blot analysis of several
molecular mediators of proliferation, survival, and cell death
processes (Figures 3C and 3D; Figure S4).We observed that, 24 h after
transfection, miR-125b induced a signiﬁcant reduction in both
expression and activity of the negative protein translational regulator
4EBP1, reaching a total absence of signal 24 h later. Furthermore, it
was observed, for the same protein, an enhancement of the inhibitory
effect when cells were electroporated with miR-125b-Omet or miR-
125b-LNA. 4EBP1 phosphorylation seemed to follow the expression
levels of the corresponding total protein.
Interestingly, at the ﬁrst time point, IL-6R, C-Raf, Akt, Bcl-2, and
Mcl-1 were slightly downregulated by miR-125b transfection; how-
ever, their expression levels were signiﬁcantly reduced or completely
inhibited following miR-125b-Omet or miR-125b-LNA transfection.
This inhibitory effect was more signiﬁcant 48 h after transfection.
Moreover, the oncogenic transcription factor STAT3 was signiﬁ-
cantly reduced already 24 h after miR-125b-Omet transfection, and
it was even further inhibited at 48 h; this effect was also found in cells
transfected with miR-125b and, partly, in cells transfected with miR-
125b-LNA. The targeting efﬁciency of both miR-125b and its modi-
ﬁed analogs was also conﬁrmed for EIF5A, particularly at 48 h. Trans-
fection with the chemically modiﬁed miR-125b analogs showed an
inhibitory effect also on p53 expression at 24 h, if compared with
the wild-type miRNA that showed a more signiﬁcant effect at 48 h.
This speciﬁc modulation, which should lead to a global oncogenic
effect, in this cellular model where p53 mutation is associated with
loss of function, was not able to affect the p53-regulated network.
The observed miR-125b-mediated inhibition of STAT3 could be one
of the putative mechanisms underlying the upregulation of miR-34a
expression induced by miR-125b replacement. In fact, it is already
known that STAT3 downregulates miR-34a, and, therefore, miR-
125b could be involved in the feedback loop IL-6R/STAT3/miR-34a
described by Rokavec et al.57 This mechanism, as well as the
Figure 3. Modulation of Both miR-125b Targets and
miR-34a Expression in MM Cells after Ectopic
Expression of miR-125b or Its Modified Analogs
(A) Analysis of basal miR-34a levels by qRT-PCR in
SKMM-1, RPMI 8226, U266, OPM-2, and KMS-12 cell
lines. Each experiment was repeated at least three times
and data are shown as mean ± SD. (B) miR-34a levels in
U266 MM cell lines after ectopic expression of miR-125b
mimics or its modified analogs. Analysis of miR-34a levels
by qRT-PCR is shown in the U266 cell line after 48 h from
transfection with 100 nMmiR-125b, miR-NC, miR-125b-
Omet (Omet), miR-125b-LNA (LNA), or miR-125b-20F (F).
Each experiment was repeated at least three times and
data are shown as mean ± SD. *p% 0.05, **p% 0.01. (C
and D) Western blot analysis of U266 cells transfected
with 100 nM miR-125b, miR-NC, miR-125b-Omet
(Omet), miR-125b-LNA (LNA), or miR-125b-20F (F). After
24 h (C) and 48 h (D) from transfection, the cells were
collected for western blotting analysis. Subsequently, the
expressions of IL6-R, cRaf, Akt, Bcl-2, Mcl1, STAT3,
pSTAT3, EIF5A, 4EBP1, p4EBP1, and p53 were evalu-
ated after blotting with specific antibodies, as described in
theMaterials andMethods. The actin protein was used as
a loading control. (E) Scheme representing the molecular
mechanism of miR-125b-induced oncosuppressive
effect. Bcl-2, Mcl-1, IL-6R, and STAT3 are miR-125b
validated targets, as we have herein demonstrated.
STAT3 has a great impact in transcriptional activation of
pro-survival mediators Bcl-2 andMcl-1 and, in turn, Bcl-2
can induce STAT3 activation.7,89 STAT3 silencing by
miR-125b inhibits Bcl-2 and Mcl-1 expressions, already
repressed by miR-125b itself. In addition, the miR-125b-
mediated simultaneous inhibition of IL-6R and STAT3
induces a clear upregulation of the tumor suppressor
miR-34a, which, in turn, can further down-modulate
IL-6R expression.
www.moleculartherapy.orginterference of miR-125b with other targets involved in the regulation
of apoptosis, autophagy, and senescence, have been described in
Figure 3E.
Overall, the target’s silencing induced bymiR-125b-Ometwas observed
earlier thanmiR-125b-LNA andmiR-125b-20F, while a slight effect was
observed 24 h after not-modiﬁed-miR-125b transfection. Moreover, in
most cases, the effect on target protein expression was lost or strongly
reduced at 48 h in cells transfected with miR-125b-20F.Molecular TThese data suggest that miR-125b transfection
and, more signiﬁcantly, miR-125b-Omet and
miR-125b-LNA transfections, induce a consid-
erable perturbation of the major mediators of
cell death and proliferation processes in the
U266 cell line.
Cell Death Processes Induced by miR-125b
Replacement
To investigate the functional role of miR-125b,
we studied the possible induction of apoptosisand/or autophagy in the U266 cell line. In detail, cells transfected
without or with miR-NC, miR-125b, miR-125b-Omet, miR-125b-
LNA, andmiR-125b-20F were stained with Annexin V and propidium
iodide (PI) or with Monodansylcadaverine (MDC) and processed for
ﬂow cytometry at 24, 48, and 72 h from transfection. The results
showed that both miR-125b and miR-125b-Omet transfection
induced a signiﬁcant increase in late apoptotic cells after 72 h (Figures
4A and 4B), although no evidence of apoptosis was observed in pre-
vious times (Figure S5). On the other hand, the same treatmentsherapy: Nucleic Acids Vol. 16 June 2019 397
Table 2. Predicted miR-125b Targets
NA, not applicable; PCT, probability of conserved targeting.
Molecular Therapy: Nucleic Acidsinduced, at 48 h, a great increase inmean ﬂuorescence intensity (MFI)
due to MDC-positive staining, compared to untreated or miR-NC-
transfected cells (Figures 4C and 4D; Figure S6). In detail, the ﬂuores-
cence intensity was increased by 2.3-fold in miR-125b-transfected
cells and by 1.6- to 1.7-fold in cells transfected with the other oligo-
nucleotides. Notably, we also observed a modulation of autophagy
markers; speciﬁcally, both Atg7 levels and LC3-II:I ratio were
increased by miR-125b and chemically modiﬁed oligonucleotides if
compared to the untreated cells, as clear indication of an augmented
number of autophagosomes with the most signiﬁcant upregulation
found in cells treated with miR-125b-Omet (Figures 4E and 4F). Au-
tophagic vesicle acidiﬁcation was, instead, reverted at 72 h (Figure S7)
when apoptosis occurrence was detected (Figures 4A and 4B).
Overall, these data suggest that autophagic ﬂux, initially activated as a
cytoprotective process able to inhibit apoptosis, is subsequently
blocked with a consequent increase in apoptosis activation.
Senescence Occurrence after miR-125b Replacement
Based on the current knowledge that describes senescence as a process
that can trigger autophagy as a mechanism of adaptation to the398 Molecular Therapy: Nucleic Acids Vol. 16 June 2019stress25,32 and, at the same time, as a process that reduces cell reac-
tivity to apoptotic stimuli,33 we also investigated, at the same experi-
mental conditions, the possible occurrence of senescence. The results
obtained by cytochemical b-galactosidase assay indicated a marked
activation of the senescence in correspondence with transfection
with each of the three chemically modiﬁed oligonucleotides; in partic-
ular, already at 24 h (Figure 5A), about 60% senescence was observed
after transfection with either miR-125b-Omet or miR-125b-LNA and
48%with the ﬂuorinated miRNA. At the subsequent time (Figure 5B),
also miR-125b induced an increase (58%) of senescent cells, and an
additional potentiation (up to 70%) of the pro-senescence effect
induced by miR-125b-Omet was found. As a conﬁrmation of senes-
cence induction, we also analyzed, by western blotting, the modula-
tion of the main senescence mediators p21, p27, and p16 (Figure 5C).
In detail, the extent of protein expression levels was signiﬁcantly
higher compared to control cells 24 h after miR-125b or miR-125b-
Omet transfection, while miR-125b-LNA induced a protein increase
to a lesser extent, limited to p21 and p27. Microscopic analysis of
b-galactosidase-positive cells is shown in Figure 5D. b-galactosidase
activity was almost completely abolished 72 h after transfection
(Figure S8).
Figure 4. Analysis of Apoptosis and Autophagy Modulation
(A and B) The U266 cell line was transfected with miR-125b, miR-NC, or miR-125b-Omet at a final concentration of 100 nM for 72 h. After double staining with PI and Annexin
V, as described in the Materials and Methods, cells were analyzed by flow cytometric analysis. (A) UL, upper left (necrosis); UR, high to right (in late apoptosis); LL, low left
(viable); LR, lower right (early apoptosis); CTR, untreated cells. The data are representative of three different experiments that have always yielded similar results. The results
are shown as cell percentage in the respective quadrants. (B) Stacked bar histogram represents the percentage of cells in the four quadrants. See also Figure S2 for 24- and
48-h fluorescence-activated cell sorting (FACS) analysis of apoptosis. (C) The U266 cell line was transfected with miR-125b, miR-NC, miR-125b-Omet (Omet), miR-125b-
LNA (LNA), or miR-125b-20F (F) at a final concentration of 100 nM for 48 h. After monodansylcadaverine (MDC) staining, cells were analyzed on the BD Accuri C6 flow
cytometer. (D) The histogram shows the relative mean fluorescence intensity (MFI) with respect to the control sample. The results are shown as means ± SD for three in-
dependent experiments. *p% 0.05, **p% 0.01. See also Figure S7 for 72-h FACS analysis of autophagy. (E) The U266 cell line was transfected with miR-125b, miR-NC,
miR-125b-Omet (Omet), miR-125b-LNA (LNA), or miR-125b-20F (F) at a final concentration of 100 nM. After 48 h from transfection, the cells were collected for western
blotting analysis. Subsequently, the expressions of Atg7 and LC3B I and II, was evaluated after blotting with specific antibodies, as described in the Materials and Methods.
The actin protein was used as a loading control. (F) The histogram shows the ratio between the LC3 II and LC3 I forms. Densitometry analysis was performed using the ImageJ
analysis tool. *p% 0.05, **p% 0.01.
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Figure 5. Analysis of Senescence
(A and B) Senescence-associated b-galactosidase assay. U266 cells were transfected with 100 nM miR-125b, miR-NC, miR-125b-Omet (Omet), miR-125b-LNA (LNA), or
miR-125b-20F (F). After 24 h (A) and 48 h (B) from transfection, cells were incubated with staining solution as described in the Materials and Methods and analyzed with a
microplate reader to determine the amount of converted substrate at 570–595 nm. The histogram shows the percent of blue cells. The results are shown as means ± SD for
three independent experiments. *p % 0.05, **p % 0.01. See also Figure S8 for 72-h analysis of b-galactosidase activity. (C) Western blotting analysis of senescence
mediators. The U266 cell line was transfected with miR-125b, miR-NC, miR-125b-Omet (Omet), miR-125b-LNA (LNA), or miR-125b-20F (F) at a final concentration of
100 nM. After 24 h from transfection, the cells were collected for western blotting analysis. Subsequently, the expressions of p21, p27, and p16 were evaluated after blotting
with specific antibodies, as described in the Materials and Methods. The actin protein was used as a loading control. (D) Microscopic analysis of positive cells to
b-galactosidase. The U266 cells were transfected with 100 nM miR-125b, miR-NC, miR-125b-Omet (Omet), miR-125b-LNA (LNA), or miR-125b-20F (F). After 48 h from
treatment, cells were observed with a bright-field microscope. Randomly selected fields were photographed at 10 and 40 magnifications.
Molecular Therapy: Nucleic AcidsOverall, early activation of senescence, in parallel with autophagy in-
duction, could be recognized as the leading cause of apoptosis inhibi-
tion at 24 and 48 h. Indeed, the decreases in both processes at 72 h give
way to apoptosis induction.400 Molecular Therapy: Nucleic Acids Vol. 16 June 2019DISCUSSION
The miR-125 family is involved in a broad variety of cellular pro-
cesses, i.e., differentiation, proliferation, and apoptosis, thereby play-
ing a crucial role in different cancers, either as tumor suppressor or
www.moleculartherapy.orgpromoter. Among the three homologs belonging to this family
(hsa-miR-125a, hsa-miR-125b-1, and hsa-miR-125-2), miR-125b is
transcribed by two loci placed on chromosomes 11q23 (hsa-miR-
125b-1) and 21q21 (hsa-miR-125b-2).58 Moreover, miR-125b-1 is
implicated in a number of chromosomal translocations correlated
with the occurrence of acute myeloid leukemia (AML) and B cell
acute lymphoid leukemia (B-ALL) or myelodysplasia.59,60 Despite
that miR-125b dysregulation has been linked to tumor-promoting ac-
tivity in different subtypes of leukemia61–63 and to drug resistance in
some cases of MM,64 we have demonstrated that miR-125b acts as an
oncosuppressor in MM by selective IRF4 inhibition.24
This study focused on the additional biochemical and functional
characterization of MM cells after miR-125b-enforced expression.
First, we selected the most suitable cell system, based on a model ex-
pressing low basal levels of miR-125b and exhibiting a signiﬁcant
antiproliferative response upon miRNA replacement. The U266 cell
was the favored model presenting, together with SKMM-1 and
OPM-2 cells, signiﬁcantly lower miR-125b levels compared to
RPMI 8226 and KMS-12 and, moreover, showing the most signiﬁcant
growth inhibition 24 and 48 h after miR-125b transfection. Most
importantly, these ﬁndings allowed us to establish a correlation be-
tween basal miR-125b expression levels and the effectiveness of the
miRNA-dependent growth-inhibitory effect by transient transfection.
Indeed, RPMI 8226 cells viability was not signiﬁcantly affected by
transiently induced miR-125b ectopic expression, compared to previ-
ous results observed by stable miRNA transfection.24 The antiproli-
ferative effect of miR-125b has been reported in several studies
involving solid tumors, such as breast,65,66 ovarian,67,68 cutaneous
squamous cell,69 hepatocellular70–72 and bladder cancers,73 osteosar-
coma,74 and melanoma.75 By contrast, a clear tumorigenic effect was
observed in endometrial carcinoma cell lines and in oligodendrog-
lial,76 pancreatic,77 prostate,78,79 and other cancers.
To better frame the molecular context, genetic proﬁling of MM cell
lines was performed. The identiﬁcation of genetic defects as common
and rare variants in candidate regions of the human genome is essen-
tial to understand the etiology of complex human diseases. By muta-
tional analysis, we identiﬁed deleterious mutations in several genes
involved in cell proliferation and differentiation processes. In detail,
U266 cells are mutated in MET, TP53, and BRAF genes; SKMM-1
cells are mutated in CSDE1 (upstream gene of NRAS), PTEN, and
TP53; RPMI 8226 cells show a greater number of mutated genes, in
particular ERBB4, PIK3CA, EGFR, KRAS, and TP53 (Table S1).
Noteworthy, these three lines present SNVs in the TP53 gene,
involving a complete or partial loss of transactivation activities, as
we found in the TP53 variants database IARC TP53 Database (R18
version)25 (Table S2). The antiproliferative role of p53 protein in
response to various stressors and during physiological processes
(e.g., senescence) makes it a primary target for inactivation in
cancer.80
Based on the evident oncosuppressive role and in order to exploit this
property in prospective studies in vivo, we designed a series of chem-ical modiﬁcations at the 20-Ribose (20-Omet, 20-F, and LNA) to confer
both nuclease resistance in the biological environment and increased
stability and/or binding speciﬁcity of the miRNA-mRNA duplex.
Indeed, RNA degradation mechanisms catalyzed by nucleases largely
involve the 20-OH of the ribose moiety,81 so that its chemical modi-
ﬁcations should result in an improved stability. Moreover, the inser-
tion of a chemical moiety in the 20 position favors the characteristic
double-helix conformation of the miRNA-mRNA duplex. The anti-
proliferative effect induced by chemically modiﬁed oligonucleotides
clearly demonstrated their efﬁcacy in counteracting MM cell viability
and, consequently, their role as miR-125b mimic with additional
enhanced growth-inhibitory properties. Perturbations in the miRNA
expression proﬁle by miR-125b replacement were investigated in
U266 cells, highlighting several up- and downregulated miRNAs,
most of which are already characterized in cancer but not yet
speciﬁcally in MM. Among these, we validated the ubiquitous onco-
suppressive miR-34a, whose molecular mechanisms mediating anti-
MM activity were already reported in our previous papers.9,13,14,16,17
Performing a comprehensive in silico search for miR-125b target
prediction, we identiﬁed a panel of putative mRNA targets playing
important roles in both the induction and progression of MM, as
well as in maintaining the myeloma microenvironment. These targets
were validated by western blot analysis. In detail, IL-6R, C-Raf, Akt,
Bcl-2, Mcl-1, and EIF5A were clearly downregulated 48 h after
miR-125b transfection, although their expression levels were signiﬁ-
cantly reduced or completely inhibited already at 24 h following
miR-125b-Omet or miR-125b-LNA transfection. Silencing induced
by Omet- and LNA-modiﬁed oligonucleotides was preserved or
increased at the following time point. Of note, the oncogenic tran-
scription factor STAT3 was signiﬁcantly reduced already 24 h after
miR-125b-Omet transfection, and it was further inhibited at the sub-
sequent time; this effect was also established for cells transfected with
miR-125b and, partly, also for miR-125b-LNA-transfected cells.
Interestingly, the reduced expression of both the tumor suppressor
p53 and the translation repressor protein 4EBP1, a key negative regu-
lator of cell proliferation downstream of mTORC1, did not compro-
mise the miRNA-mediated growth-inhibitory effect. Despite the sig-
niﬁcant p53 repression, the main reason for the global growth-
inhibitory effect exerted by miR-125b may lie in the molecular
context of the U266 cell line, where p53 mutation is associated with
loss of function and its silencing does not produce the expected onco-
genic effect, sometimes observed after miR-125b replacement.
It is well established that the BMM plays a prominent role in the
biology of MM cells, since it elicits the production of cytokine, the
enhancement of cell proliferation, and the resistance to chemotherapy
by the activation of nuclear factor kB (NF-kB), PKC, PI3K/AKT, and
JAK/STAT3 pathways through the largely characterized MM growth
factor IL-6.7 These pathways actively participate in transforming
plasma cells. In detail, STAT3 has a great impact in the transcriptional
activation of pro-survival mediators Bcl-2 and Mcl-182 that are,
together with STAT3, miR-125b validated targets, as we have herein
demonstrated. Therefore, STAT3 silencing further inhibits Bcl-2 andMolecular Therapy: Nucleic Acids Vol. 16 June 2019 401
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3E). Moreover, being Bcl-2 an inducer of STAT3 activation,83 miR-
125b can exert its oncosuppressive role by interfering with this posi-
tive feedback loop. A recent study reported that IL-6-induced onco-
genic effects are mediated by the direct repression of miR-34a by
STAT3 and that the p53-dependent expression of miR-34a suppresses
tumor progression by inhibiting the IL-6R/STAT3/miR-34a feedback
loop, being IL-6R a direct target of miR-34a.26 In this context, the up-
regulation of miR-34a could be due, at least in part, to the simulta-
neous inhibition of IL-6R and STAT3 by miR-125b ectopic expres-
sion (Figure 3E).
In parallel with this oncosuppressor activity, we also observed an early
miR-125b-induced cytoprotective effect, such as the accumulation
and acidiﬁcation of autophagosomes. Indeed, autophagy is often
recognized as an anti-apoptotic process,84 and this antagonistic effect
is particularly apparent in U266 cells compared to other previously
analyzed MM models, where a slight activation of apoptosis was de-
tected at 48 h.24 However, this escape from cell death was largely over-
come by the induction of apoptosis after 72 h. Importantly, for the
ﬁrst time we have also established the induction of senescence, an
additional cell death mechanism, upon miR-125b ectopic expression
in MM cells. Accordingly, other authors have recently observed this
effect following miR-125b replacement, though exclusively for mela-
noma cells.85,86 It is well known that senescence can elicit autophagy
as a mechanism of adaptation to stress,25,32 reducing, at the same
time, cell reactivity to apoptotic stimuli.33 Overall, the observed cell
death processes associated with miR-125b ectopic expression can be
integrated as follows: early activation of senescence, in parallel with
autophagy induction, likely lead to apoptosis inhibition at 24 and
48 h, while the progressive inactivation of both processes at 72 h could
be the turning point toward apoptosis induction.
In conclusion, we have delineated the functional role of miR-125b in
MM cell models, showing an oncosuppressive function based on the
repression of multiple cancer-associated targets. For the ﬁrst time,
we identiﬁed a cross-regulation between miR-34a and miR-125b due
to their inhibitory roles on the IL-6R/STAT3/miR-34a feedback loop,
ultimately resulting in the stimulation of miR-34a expression. In this
context, we demonstrated low miR-125b basal levels correlating with
a higher efﬁcient cell growth inhibition upon miRNA replacement.
Moreover, we showed enhanced miR-125b-induced anticancer effects
in vitro by the use of chemically modiﬁed analogs. miRNA proﬁling
analysis allowed the identiﬁcation of a pattern of differentially ex-
pressed miRNAs, thus opening future perspectives for the detection
of new players in anti-MM activity. Finally, before apoptosis activation
at 72 h and concurrently with autophagy onset, we identiﬁed early
activation of senescence as the possible leading cause of apoptosis inhi-
bition at 24 and 48 h frommiR-125b ectopic expression. The anti-MM
activity revealed in vitro by chemically modiﬁed miRNAs, inhibiting
the expression of themain targets and prompting the functional effects
of miR-125b, can represent a promising starting point for prospective
preclinical investigations in vivo aimed at demonstrating the biological
stability and therapeutic efﬁcacy of these oligonucleotides.402 Molecular Therapy: Nucleic Acids Vol. 16 June 2019MATERIALS AND METHODS
Cell Cultures
U266, RPMI 8226, KMS-12, OPM-2, and SKMM-1 MM cell lines,
kindly provided by the Department of Clinical and Experimental
Medicine of the University Magna Græcia, were grown in RPMI-
1640 medium containing L-glutamine (Gibco, Life Technologies,
Carlsbad, CA, USA), supplemented with heat-inactivated 20% fetal
bovine serum (FBS) (Lonza Group, Switzerland), 20 mM HEPES,
100 U/mL penicillin, and 100mg/mL streptomycin (Gibco, Life Tech-
nologies, Carlsbad, CA, USA) and incubated at 37C in a 5% CO2
atmosphere.Next-Generation Sequencing-Based Expression Profiling in MM
Cells
The genetic proﬁles of U266, RPMI 8226, and SKMM-1 cell lines were
analyzed by sequencing using next-generation sequencing technolo-
gies. Genomic DNAwas extracted using aWizard Genomic DNA Pu-
riﬁcation Kit (Promega, USA), and quantiﬁcation was performed
with a ﬂuorometer Qubit 3.0 (Life Technologies, Thermo Fisher Sci-
entiﬁc, USA), according to themanufacturer’s instructions. Amplicon
re-sequencing strategy was used to create an amplicon library. An
amount of 10 ng DNA was ampliﬁed using Ion AmpliSeq Library
Kit 2.0 and an Ion AmpliSeq Community panel. The resulting ampli-
cons were treated with FuPa Reagent to partially digest the primers.
The amplicons were then ligated to Ion P1 Adapters with Ion Xpress
Barcodes, using a Switch Solution andDNA Ligase, and puriﬁed using
Agencourt AMPure XP Kit. The ampliﬁed library was quantiﬁed with
Qubit 2.0 Fluorometer. Each DNA fragment is bound to a single ion
sphere particle (ISP) with the P adaptor and multiplied by clonal
ampliﬁcation so each ISP is covered with many copies of the same
DNA fragment. The clonal ampliﬁcation by emulsion PCR was
done using 100 pM diluted library on the Ion OneTouch 2 system
with Ion PI Template OT2 200 Kit version (v.)2 chemistry (Life Tech-
nologies, Thermo Fisher Scientiﬁc, USA). Enrichment was conducted
using the Ion OneTouch ES (Life Technologies, Thermo Fisher Scien-
tiﬁc, USA). The prepared samples of Ion Sphere Particles were loaded
onto an Ion 314 sequencing chip (Life Technologies) and sequenced
on the Ion Personal Genoma Machine System using an Ion PGM
Sequencing 200 Kit v.2 chemistry (200-bp read length, Life Technol-
ogies). All DNA samples were analyzed with an Ion AmpliSeq Panel
for somatic mutation detection. This panel has primer pairs in a single
pool for hotspots and targeted regions for 22 genes: KRAS, EGFR,
BRAF, PIK3CA, AKT1, ERBB2, PTEN, NRAS, STK11, MAP2K1,
ALK, DDR2, CTNNB1, MET, TP53, SMAD4, FBX7, FGFR3,
NOTCH1, ERBB4, FGFR1, and FGFR2. The panel also includes
primers for 3 additional amplicons covering target regions of the
NRAS and ALK genes: NRAS exon 4 variants (p.117, p.146) and
ALK variants (G1269A, p.S1206Y). Base calling and elaboration
were executed by the Torrent Suite (Life Technologies, Thermo Fisher
Scientiﬁc, USA) and Ion Reporter (https://ionreporter.thermoﬁsher.
com/ir/), which generated VCF ﬁles. To evaluate the reliability of
the obtained result, the following parameters were considered: chip
loading (percent of the chip wells physically ﬁlled with spheres,
www.moleculartherapy.orgISP), enrichment (percent of spheres enriched with monoclonal li-
braries), and coverage (number of reads that include a given nucleo-
tide in the reconstructed sequence). The data obtained are aligned
against the human reference genome hg19 (ﬁled by the Genome
Reference Consortium).20-Omet, LNA, and 20-F Oligonucleotide Synthesis and
Purification
The 20-Omet, LNA, and 20-F oligonucleotides were synthesized
by a Millipore Cyclone Plus DNA synthesizer at a 1-mmol scale,
using commercially available 50-O-(4,4’-dimethoxytrityl)-20-O-
methyl-30-O-(2-cyanoethyl-N,N-diisopropyl) RNA phosphoramidite
monomers and 20-Omet RNA SynBaseCPG 1000/110 as solid-phase
support (Link Technologies). The oligomers were detached from the
support and deprotected by treatment with concentrated aqueous
ammonia at 55C for 12 h. The combined ﬁltrates and washings
were concentrated under reduced pressure, dissolved in H2O,
analyzed, and puriﬁed by anion-exchange high-performance liquid
chromatography (HPLC) by a Nucleogel SAX column (Macherey-
Nagel, 1000-8/46), using buffer A (20mMKH2PO4/K2HPO4 aqueous
solution [pH 7.0] containing 20% [v/v] CH3CN) and buffer B (1 M
KCl and 20 mM KH2PO4/K2HPO4 aqueous solution [pH 7.0] con-
taining 20% [v/v] CH3CN); a linear gradient from 0% to 100% B
for 45 min and a ﬂow rate of 1 mL/min were used. The puriﬁed olig-
omers were successively desalted by Sep-Pak C-18 cartridges (Waters)
and characterized by ESI mass spectrometry.In Vitro Transfection of MM Cell Lines
The miR-125b mimic was synthesized “in service” from the research
laboratories of CEINGE (Biotecnologie Avanzate, Napoli, Italy). The
sequence of the miR-125b mimic was 50-UCCCUGAGACCCUAA
CUUGUGA-30. The sequence of the NC mimic was 50-GCAA
UUUGGCGUCCUCCACUAA-30. The MM cell lines were seeded at
a density of 112 103 cells/cm2 in RPMI medium without antibiotics,
and they were electroporated with miR-125b mimics and its modiﬁed
analogs, at a ﬁnal concentration of 100 nmol/L, using a Neon Transfec-
tion System (Invitrogen, Carlsbad, CA, USA; 1,050 V, for 30 ms, 1
pulse). An oligonucleotide with scrambled sequence (miRNA-NC)
(Life Technologies, Carlsbad, CA, USA) at a concentration of
10 nmol/L was used as a control. Cell transfection efﬁciency was eval-
uated by ﬂow cytometric analysis after ﬂuorochrome-labeled oligonu-
cleotide (FAM) (Invitrogen, Carlsbad, CA) transfection.Cell Viability and Proliferation Assays
MM cell lines were electroporated, as previously described, and a
viability assay was performed using Cellometer Auto 1000 (Nexcelom
Bioscience, Lawrence, MA, USA) after trypan blue 0.2% staining
(Lonza Walkersville), according to the manufacturer’s instructions.
Cell proliferation was evaluated by MTS colorimetric assay. CellTiter
96 AQueous One Solution Cell Proliferation assay (Promega, Milan,
Italy) was used to determine cell growth, according to the manufac-
turer’s instructions. The absorbance values at 492 nm were corrected
by subtracting the average absorbance from the control wells contain-ing only the cell medium. Each experiment was performed in tripli-
cate and data were expressed as mean ± SD.Western Blot Analysis
The U266 MM cell lines were electroporated with or without miR-
125b mimics and its modiﬁed analogs, as previously described. For
cell extract preparation, cells were washed twice with ice-cold PBS
and BSA and centrifuged for 30 min at 4C in 1 mL lysis buffer
(1% Triton, 0.5% sodium deoxycholate, 0.1 M NaCl, 1 mM EDTA
[pH 7.5], 10 mM Na2HPO4 [pH 7.4], 10 mM phenylmethylsulfonyl
ﬂuoride [PMSF], 25 mM benzamidin, 1 mM leupeptin, and
0.025 U/mL aprotinin). Lysates were spun at 13,000  g for 10 min
and supernatants were collected.87 Protein concentration was deter-
mined by the Lowry method and compared with BSA standard curve.
Equal amounts of cell proteins were separated by SDS-PAGE using
TGX Stain-Free FastCast Acrylamide Solutions (Bio-Rad, CA,
USA). The proteins were electro-transferred to nitrocellulose by
Trans blot turbo (Bio-Rad, CA, USA) and reacted with the different
monoclonal antibodies (mAbs). Stat3, p-Stat, and Mcl-2 mAbs were
purchased from Santa Cruz Biotechnology (Dallas, TX, USA).
4-EBP1, p-4EBP1, Eif5A, p53, Craf, IL-6R, Akt, LC3B I and II, and
Atg7 mAbs were purchased from Cell Signaling Technology (Beverly,
MA, USA). Anti-actin mAb was purchased from Sigma-Aldrich
(USA). After incubation with secondary antibodies, the signal was de-
tected using Immobilon Western Chemiluminescent HRP Substrate
(ECL, Millipore, MA, USA). Actin expression levels were used as
the loading control in each sample. Densitometry analysis was per-
formed using the ImageJ analysis tool.Real-Time qPCR
Total RNA from MM cell lines was obtained by mirVana miRNA
Isolation Kits (Life Technologies), according to themanufacturer’s in-
structions. The quality and quantity of RNA were assessed by the
NanoDrop ND-1000 Spectrophotometer (Thermo Scientiﬁc, Wil-
mington, DE, USA). Oligo-dT-primed cDNA was obtained using
the High Capacity cDNA Reverse Transcription Kit (Applied
Biosystems, CA, USA). The single-tube TaqManmiRNA assays (Am-
bion, Life Technologies, CA, USA) were used to detect and to quantify
mature miR-125b and miR-34a, according to the manufacturer’s in-
structions, by Real-time PCR Viia7 (Applied Biosystems, CA, USA).
miR-125b and miR-34a expressions were normalized with RNU44
(Ambion, Life Technologies, CA, USA). Comparative real-time
PCR was performed in triplicate, including no template controls,
and relative expression was calculated using the comparative cross-
threshold (Ct) method.Flow Cytometric Analysis of Autophagy
The autophagy evaluation was performed after MDC (Sigma, USA)
staining, a selective autophagolysosome marker.88 The MM cell lines
were electroporated in our experimental condition and incubated
with 50 mM MDC for 10 min at 37C and washed twice in PBS.
The autophagic cell analysis was performed by ﬂow cytometry (BD
Accuri C6). For each sample, 1  104 events were acquired. EachMolecular Therapy: Nucleic Acids Vol. 16 June 2019 403
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mean ± SD.
Senescence-Associated b-Galactosidase Assay
U266 cells, with miR-125b mimic- or modiﬁed analog-enforced
expression, were ﬁxed with 2% formaldehyde and 0.2% glutaralde-
hyde for 5 min at room temperature (RT), then incubated overnight
with Staining Solution (5 mMK3Fe(CN)6, 5 mMK4Fe(CN)6, 150mM
NaCl, 2 mM MgCl2, and X-Gal 1 mg/mL [Promega, USA]) in 0.2 M
citric acid and 1 M Na phosphate buffer (pH 6.0). The cells were
rinsed twice with PBS before microplate reader (iMark Microplate
Absorbance Reader, Bio-Rad Laboratories, Hercules, CA, USA)
analysis at 570–595 nm or microscopic examination. Concerning
microscopic examination, the number of b-galactosidase active and
senescent cells was determined by counting blue cells under a Nikon
Eclipse TS100 model light microscope, and randomly selected ﬁelds
were photographed at 10 and 40 magniﬁcations.
Microarray Screening Assay
In miRNA screening assay, U266 cells were transfected with 100 nM
miR-125b, miR-125b-omet, or miR-NC, and RNA was extracted 48 h
later as described above. Starting from RNA 60 ng of each sample was
synthesized cDNA with Megaplex RT Primers, Human Pool A v.2.1
(Applied Biosystems, CA, USA), according to the manufacturer’s in-
structions. Human Pool A v.2.1 contains RT primers for 377 unique
miRNAs and 4 controls. The miRNA expression proﬁling was subse-
quently performed using TaqMan Array HumanMicroRNA A Cards
v.2.0 (Applied Biosystems, CA, USA) and TaqMan Universal PCR
Master Mix (Applied Biosystems, CA, USA), following the manufac-
turer’s manuals. The assay was run on Viia 7 real-time PCR system
(Applied Biosystems, CA, USA).
The Ct value of every miRNA was determined using Viia7 software
(Applied Biosystems, CA, USA) and setting a threshold of 0.2. For
calculation of the DCt for the miRNAs of interest, Ct values of every
miRNA were normalized by RNU44 small nucleolar RNA (snoRNA)
as an endogenous control. The relative miRNA expression was calcu-
lated with the DDCt method. Fold change was calculated with the
2DDCt method.
Statistical Analysis
Statistical analysis was performed using ANOVA. Signiﬁcant differ-
ences were determined at p % 0.05 according to the Student’s
t test. Graphs were obtained using SigmaPlot v.11.0 (Systat Software,
San Jose, CA, USA).
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